UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future

Current topics in medicinal chemistry, 2016-12, Vol.16 (29), p.3385-3403

2016

Volltextzugriff (PDF)

Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans

Proceedings of the National Academy of Sciences - PNAS, 2011-05, Vol.108 (22), p.9262-9267

2011

Volltextzugriff (PDF)

Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission

Psychopharmacology, 2015-02, Vol.232 (3), p.605-621

2015

Volltextzugriff (PDF)

Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders

Journal of medicinal chemistry, 2014-03, Vol.57 (6), p.2670-2682

2014

Volltextzugriff (PDF)

Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment

Current pharmaceutical design, 2014-01, Vol.20 (31), p.5093-5103

2014

Volltextzugriff (PDF)

Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial

The American journal of psychiatry, 2021-12, Vol.178 (12), p.1098-1106

2021

Volltextzugriff (PDF)

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial

JAMA psychiatry (Chicago, Ill.), 2020-04, Vol.77 (4), p.349

2020

Volltextzugriff (PDF)

Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia

Schizophrenia research, 2021-02, Vol.228, p.198-205

2021

Volltextzugriff (PDF)

Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials

International clinical psychopharmacology, 2021-09, Vol.36 (5), p.244-250

2021

Volltextzugriff (PDF)

Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2019-02, Vol.44 (3), p.598-605

2019

Volltextzugriff (PDF)

Dopamine D 2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2019-02, Vol.44 (3), p.598

2019

Volltextzugriff (PDF)

Effect Size and Blinding in Lumateperone Trial-Reply

JAMA psychiatry (Chicago, Ill.), 2020-06, Vol.77 (6), p.651

2020

Volltextzugriff (PDF)

Single doses of a highly selective inhibitor of phosphodiesterase 1 (lenrispodun) in healthy volunteers: a randomized pharmaco-fMRI clinical trial

Neuropsychopharmacology (New York, N.Y.), 2022-09, Vol.47 (10), p.1844-1853

2022

Volltextzugriff (PDF)

ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial

Biological psychiatry (1969), 2016-06, Vol.79 (12), p.952-961

2016

Volltextzugriff (PDF)

Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders

Psychopharmacology, 2024-07, Vol.241 (7), p.1477-1490

2024

Volltextzugriff (PDF)

ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models

The Journal of pharmacology and experimental therapeutics, 2007-08, Vol.322 (2), p.862-870

2007

Volltextzugriff (PDF)

Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial

Bipolar disorders, 2023-09, Vol.25 (6), p.478-488

2023

Volltextzugriff (PDF)

Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases

Journal of medicinal chemistry, 2016-02, Vol.59 (3), p.1149-1164

2016

Volltextzugriff (PDF)

Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats

Psychopharmacology, 2016-09, Vol.233 (17), p.3113-3124

2016

Volltextzugriff (PDF)

A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia

Advances in pharmacology (1990), 2021, Vol.90, p.253

2021

Volltextzugriff (PDF)

186 Results From a 12-Month Open-label Safety Study of Lumateperone (ITI-007) in Patients with Stable Symptoms of Schizophrenia

CNS spectrums, 2020-04, Vol.25 (2), p.317-318

2020

Volltextzugriff (PDF)

185 The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials

CNS spectrums, 2020-04, Vol.25 (2), p.316-317

2020

Volltextzugriff (PDF)

ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers

Psychopharmacology, 2015-08, Vol.232 (15), p.2863-2872

2015

Volltextzugriff (PDF)

Pharmacology of N-desmethylclozapine

Pharmacology & therapeutics (Oxford), 2007-08, Vol.115 (2), p.223-231

2007

Volltextzugriff (PDF)

ITI-007, A NEW APPROACH TO THE TREATMENT OF SCHIZOPHRENIA

Schizophrenia research, 2014-04, Vol.153, p.S21-S21

2014

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(76)

Sprache

Englisch
(75)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future

Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans

Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission

Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders

Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment

Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial

Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia

Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials

Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia

Dopamine D 2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia

Effect Size and Blinding in Lumateperone Trial-Reply

Single doses of a highly selective inhibitor of phosphodiesterase 1 (lenrispodun) in healthy volunteers: a randomized pharmaco-fMRI clinical trial

ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial

Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders

ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models

Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial

Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases

Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats

A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia

186 Results From a 12-Month Open-label Safety Study of Lumateperone (ITI-007) in Patients with Stable Symptoms of Schizophrenia

185 The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials

ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers

Pharmacology of N-desmethylclozapine

ITI-007, A NEW APPROACH TO THE TREATMENT OF SCHIZOPHRENIA

Suchergebnisse filtern